|Bid||41.79 x 1200|
|Ask||41.85 x 800|
|Day's Range||41.17 - 43.35|
|52 Week Range||38.62 - 85.00|
|Beta (3Y Monthly)||2.18|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 30, 2019 - Nov 4, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||80.44|
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
How far off is Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) from its intrinsic value? Using the most recent financial...
Agios (AGIO) incurs wider-than-expected loss in Q2 while revenues beat estimates. The company's newly approved leukemia drug Tibsovo sees a rise in sales sequentially.
Agios Pharmaceuticals (AGIO) delivered earnings and revenue surprises of -8.09% and 6.43%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Strong Topline Performance for IDH Inhibitors: TIBSOVO® Net Revenue Increased 50% from Q1 2019 to $13.7M; IDHIFA® Royalty Increased to $2.7M Achieved Important Expansion.
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company will host a conference call and live webcast on Thursday, August 1, 2019 at 8:00 a.m. ET to report its second quarter 2019 financial results and other business highlights. A live webcast can be accessed under "Events & Presentations" in the Investors section of the company's website at www.agios.com. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology.
Agios Pharmaceuticals Inc NASDAQ/NGS:AGIOView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | NeutralShort interest is moderately high for AGIO with between 10 and 15% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding AGIO is favorable, with net inflows of $5.05 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the appointment of Orlando Oliveira to the role of senior vice president and general manager, international, who will be responsible for building and leading the company’s operations outside of the U.S. in support of the expected launch of TIBSOVO® in Europe and potentially other select markets. Mr. Oliveira will be based in Zug, Switzerland and report to Jackie Fouse, Ph.D., chief executive officer at Agios.
Investors can approximate the average market return by buying an index fund. When you buy individual stocks, you can...
Looking for stocks with high upside potential? Just follow the big players within the hedge fund industry. Why should you do so? Let’s take a brief look at what statistics have to say about hedge funds’ stock picking abilities to illustrate. The Standard and Poor’s 500 Index returned approximately 12.1% in 2019 (through May 30th). Conversely, hedge […]
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the company is scheduled to present at the Goldman Sachs Global Healthcare Conference in Rancho Palos Verdes, California on Tuesday, June 11, 2019 at 2:40 p.m. PT. Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism and adjacent areas of biology. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.
One of Massachusetts' leading life sciences venture capital firms has raised its largest ever fund, collecting $770 million to invest in new startups. Third Rock Ventures LLC closed its fifth fundraising this week, the company stated in a press release.
Agios Pharmaceuticals, Inc. (AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced the planned retirement of its chief scientific officer, Scott Biller, Ph.D. Dr. Biller will retire from his CSO position at the end of 2019 and continue to serve as a strategic advisor through the end of 2020. Under his leadership, the team has built a robust preclinical pipeline and advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage clinical programs,” said Jackie Fouse, Ph.D., chief executive officer at Agios. “It has been a privilege and honor to be a part of the Agios team for nearly a decade and to work toward our shared vision of making a meaningful impact on the lives of patients,” said Dr. Biller.
– With Longer Follow Up, CR+CRh Rate Increased to 70% and CR Rate Increased to 61% in the Phase 1 Study of TIBSOVO® in Combination with Azacitidine – – Phase 1 Data of Single.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios' (AGIO) Tibsovo achieves the primary goal in a late-stage development that examined it for the previously treated IDH1 mutant cholangiocarcinoma. Shares rise in after-hours trading.